Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-066731
Filing Date
2025-07-09
Accepted
2025-07-09 16:50:36
Documents
21
Period of Report
2025-08-29

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A tm2520034-2_def14a.htm   iXBRL DEF 14A 666935
6 GRAPHIC bc_paidvsnetloss-bw.jpg GRAPHIC 42163
7 GRAPHIC bc_paidvstsr-bw.jpg GRAPHIC 43223
8 GRAPHIC lg_therivabiologics-bwlr.jpg GRAPHIC 15069
9 GRAPHIC px_25therivaannual1-bw.jpg GRAPHIC 306270
10 GRAPHIC px_25therivaannual2-bw.jpg GRAPHIC 205437
  Complete submission text file 0001104659-25-066731.txt   2983188

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tovx-20241231.xsd EX-101.SCH 9826
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tovx-20241231_def.xml EX-101.DEF 2630
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tovx-20241231_lab.xml EX-101.LAB 35737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tovx-20241231_pre.xml EX-101.PRE 1781
23 EXTRACTED XBRL INSTANCE DOCUMENT tm2520034-2_def14a_htm.xml XML 195376
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12584 | Film No.: 251114076
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)